Consumer Product Safety Commission January 2012 – Federal Register Recent Federal Regulation Documents
Results 1 - 11 of 11
CPSC Symposium on Phthalates Screening and Testing Methods
The Consumer Product Safety Commission (``CPSC,'' ``Commission,'' or ``we'') is announcing its intent to hold a symposium on phthalates screening and testing methods. The symposium will be held at the CPSC's National Product Testing and Evaluation Center in Rockville, Maryland, on March 1, 2012. We invite interested parties to participate in or attend the symposium and to submit comments.
Hewlett-Packard Company, Provisional Acceptance of a Settlement Agreement and Order
It is the policy of the Commission to publish settlements which it provisionally accepts under the Consumer Product Safety Act in the Federal Register in accordance with the terms of 16 CFR 1118.20(e). Published below is a provisionally-accepted Settlement Agreement with Hewlett-Packard Company, containing a civil penalty of $425,000.00, within twenty (20) days of service of the Commission's final Order accepting the Settlement Agreement.\1\
Products Containing Imidazolines Equivalent to 0.08 Milligrams or More
The Consumer Product Safety Commission (``CPSC,'' ``Commission,'' or ``we'') is proposing a rule to require child- resistant (``CR'') packaging for any over-the-counter or prescription product containing the equivalent of 0.08 milligrams or more of an imidazoline, a class of drugs that includes tetrahydrozoline, naphazoline, oxymetazoline, and xylometazoline, in a single package. Imidazolines are a family of drugs that are vasoconstrictors indicated for nasal congestion and/or ophthalmic irritation. Products containing imidazolines can cause serious adverse reactions, such as central nervous system (``CNS'') depression, decreased heart rate, and depressed ventilation in children treated with these drugs or who accidentally ingest them. Based on the scientific data, the Commission preliminarily finds that availability of 0.08 milligrams or more of an imidazoline in a single package, by reason of its packaging, is such that special packaging is required to protect children under 5 years old from serious personal injury or illness due to handling, using, or ingesting such a substance. We are taking this action under the Poison Prevention Packaging Act of 1970 (``PPPA'').\1\
Teleconference and Public Meeting of the Chronic Hazard Advisory Panel on Phthalates and Phthalate Substitutes
The Consumer Product Safety Commission (``CPSC'' or ``Commission'') is announcing a teleconference and the seventh meeting of the Chronic Hazard Advisory Panel (CHAP) on phthalates and phthalate substitutes. The Commission appointed this CHAP on April 14, 2010, to study the effects on children's health of all phthalates and phthalate alternatives, as used in children's toys and child care articles, pursuant to section 108 of the Consumer Product Safety Improvement Act of 2008 (CPSIA) (Pub. L. 110-314). The CHAP will discuss its progress toward completing its analysis of potential risks from phthalates and phthalate substitutes.
Petition Requesting Exception From the Lead Content Limits; Reopening of the Comment Period
The Consumer Product Safety Commission (``Commission'' or ``CPSC'' or ``we'' or ``us'') has received a petition requesting an exception from the 100 ppm lead content limit under section 101(b) of the Consumer Product Safety Improvement Act of 2008 (``CPSIA''), as amended by Public Law 112-28. We are reopening the comment period for 30 days.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
